NASDAQ: LGNDLigand Pharmaceuticals Revenue
Ligand Pharmaceuticals revenue was $268.09M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $59.7M, down 48.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, LGND annual revenue was $268.1M, with 60.4% growth year-over-year.
LGND past revenue growth
How has LGND's revenue growth performed historically?
Company
60.4%
Industry
465.24%
Market
90.32%
LGND's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
LGND's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
LGND's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
LGND revenue history
Current Revenue
$268.1M
Current Earnings
$124.5M
Current Profit Margin
46.4%
LGND's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when LGND announces revenue.
LGND Revenue History By Year
| LGND Yearly Revenue | LGND Revenue | LGND Change | LGND Revenue Growth |
|---|---|---|---|
| 2025-12-31 | $268.09M | $100.95M | +60.40% |
| 2024-12-31 | $167.13M | $35.82M | +27.28% |
| 2023-12-31 | $131.31M | -$64.93M | -33.09% |
| 2022-12-31 | $196.25M | -$45.30M | -18.75% |
| 2021-12-31 | $241.54M | $77.98M | +47.68% |
| 2020-12-31 | $163.56M | $43.28M | +35.98% |
| 2019-12-31 | $120.28M | -$131.17M | -52.17% |
| 2018-12-31 | $251.45M | $110.35M | +78.21% |
| 2017-12-31 | $141.10M | $32.13M | +29.48% |
| 2016-12-31 | $108.97M | $37.06M | +51.53% |
| 2015-12-31 | $71.91M | $7.38M | +11.43% |
| 2014-12-31 | $64.54M | $15.57M | +31.78% |
| 2013-12-31 | $48.97M | $17.59M | +56.02% |
| 2012-12-31 | $31.39M | $1.35M | +4.50% |
| 2011-12-31 | $30.04M | $6.50M | +27.61% |
| 2010-12-31 | $23.54M | -$15.40M | -39.55% |
| 2009-12-31 | $38.94M | $11.63M | +42.56% |
| 2008-12-31 | $27.32M | $14.42M | +111.84% |
| 2007-12-31 | $12.89M | $8.92M | +224.21% |
| 2006-12-31 | $3.98M | -$6.24M | -61.07% |
| 2005-12-31 | $10.22M | -$101.90M | -90.89% |
| 2004-12-31 | $112.11M | $30.99M | +38.21% |
| 2003-12-31 | $81.12M | $9.35M | +13.03% |
| 2002-12-31 | $71.77M | -$4.57M | -5.99% |
| 2001-12-31 | $76.34M | $28.23M | +58.68% |
| 2000-12-31 | $48.11M | $7.22M | +17.64% |
| 1999-12-31 | $40.90M | $23.22M | +131.40% |
| 1998-12-31 | $17.67M | -$34.03M | -65.82% |
| 1997-12-31 | $51.70M | $14.86M | +40.33% |
| 1996-12-31 | $36.84M | $12.33M | +50.28% |
| 1995-12-31 | $24.52M | $11.21M | +84.21% |
| 1994-12-31 | $13.31M | N/A | N/A |
Ligand Pharmaceuticals Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.